If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is how its current share price lines up with what the business may be worth. The stock ...

CRISPR/Cas-based biosensors offer an opportunity to quantify neuroinflammation in Parkinson’s disease, advancing diagnostics ...

Using a CRISPR-based biosensor platform, researchers have detected microRNA biomarkers of Alzheimer’s disease, with the ...

These two biotechs have a lot in common. Their differences are even more pronounced.

A recent study utilizing cryo-EM advances our understanding of how bacterial immune systems function and reveals new aspects ...

The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.

If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...

Gene editing is a numbers game. For any genetic tweaks to have notable impact, a sufficient number of targeted cells need to have the disease-causing gene deleted or replaced. Despite a growing ...

CRISPR Therapeutics’ fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these early quarterly numbers don’t mean much. The foreseeable future looks bright ...

If you never eat grapefruit because you find them far too bitter, CRISPR varieties may be more to your taste. It has been shown that disabling one gene via gene editing can greatly reduce the level of ...

A new CRISPR-based one-off procedure that lowers "bad" cholesterol is expected to enter Phase I human trial in 2026. If successful, it could be the first approved genetic-silencing method on the ...